Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liposarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Liposarcoma - Overview 8
Liposarcoma - Therapeutics under Development by Companies 9
Liposarcoma - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Liposarcoma - Products under Development by Companies 13
Liposarcoma - Companies Involved in Therapeutics Development 14
Adaptimmune Therapeutics Plc 14
Amgen Inc 15
Cellceutix Corp 16
Eli Lilly and Company 17
Horizon Pharma Plc 18
Immune Design Corp 19
Karyopharm Therapeutics Inc 20
Merck & Co Inc 21
Mirati Therapeutics Inc 22
Novartis AG 23
Pfizer Inc 24
Liposarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
abemaciclib - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AMG-232 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CMB-305 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
everolimus - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
GSK-3377794 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HDM-201 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
interferon gamma-1b - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Kevetrin - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
palbociclib - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
pazopanib hydrochloride - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
pembrolizumab - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
ribociclib succinate - Drug Profile 130
Product Description 130
Mechanism Of Action 130
R&D Progress 130
selinexor - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
sirolimus - Drug Profile 152
Product Description 152
Mechanism Of Action 152
R&D Progress 152
sitravatinib - Drug Profile 153
Product Description 153
Mechanism Of Action 153
R&D Progress 153
Vimo-101 - Drug Profile 156
Product Description 156
Mechanism Of Action 156
R&D Progress 156
Liposarcoma - Dormant Projects 157
Liposarcoma - Discontinued Products 158
Liposarcoma - Product Development Milestones 159
Featured News & Press Releases 159
Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma 159
Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159
Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 161
Disclaimer 162

List of Tables
Number of Products under Development for Liposarcoma, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 14
Liposarcoma - Pipeline by Amgen Inc, H2 2016 15
Liposarcoma - Pipeline by Cellceutix Corp, H2 2016 16
Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016 17
Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016 18
Liposarcoma - Pipeline by Immune Design Corp, H2 2016 19
Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 20
Liposarcoma - Pipeline by Merck & Co Inc, H2 2016 21
Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016 22
Liposarcoma - Pipeline by Novartis AG, H2 2016 23
Liposarcoma - Pipeline by Pfizer Inc, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Liposarcoma - Dormant Projects, H2 2016 157
Liposarcoma - Discontinued Products, H2 2016 158

List of Figures
Number of Products under Development for Liposarcoma, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Top 10 Targets, H2 2016 26
Number of Products by Stage and Top 10 Targets, H2 2016 26
Number of Products by Top 10 Mechanism of Actions, H2 2016 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29
Number of Products by Routes of Administration, H2 2016 32
Number of Products by Stage and Routes of Administration, H2 2016 32
Number of Products by Molecule Types, H2 2016 34
Number of Products by Stage and Molecule Types, H2 2016 34